Bloos, Frank ORCID: 0000-0002-0767-7941, Held, Juergen, Kluge, Stefan ORCID: 0000-0001-8391-3988, Simon, Philipp, Kogelmann, Klaus, de Heer, Geraldine, Kuhn, Sven-Olaf, Jarczak, Dominik ORCID: 0000-0003-0480-2089, Motsch, Johann, Hempel, Gunther, Weiler, Norbert, Weyland, Andreas, Druener, Matthias, Gruendling, Matthias, Meybohm, Patrick, Richter, Daniel, Jaschinski, Ulrich, Moerer, Onnen, Guenther, Ulf, Schaedler, Dirk, Weiss, Raphael, Putensen, Christian, Castellanos, Ixchel, Kurzai, Oliver, Schlattmann, Peter, Cornely, Oliver A. ORCID: 0000-0001-9599-3137, Bauer, Michael and Thomas-Rueddel, Daniel (2022). (1 -> 3)-beta-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial. Intensive Care Med., 48 (7). S. 865 - 876. NEW YORK: SPRINGER. ISSN 1432-1238

Full text not available from this repository.

Abstract

Purpose: To investigate whether (1 -> 3)-beta-d-Glucan (BDG)-guidance shortens time to antifungal therapy and thereby reduces mortality of sepsis patients with high risk of invasive Candida infection (ICI). Methods: Multicenter, randomized, controlled trial carried out between September 2016 and September 2019 in 18 intensive care units enrolling adult sepsis patients at high risk for ICI. Patients in the control group received targeted antifungal therapy driven by culture results. In addition to targeted therapy, patients in the BDG group received antifungals if at least one of two consecutive BDG samples taken during the first two study days was >= 80 pg/mL. Empirical antifungal therapy was discouraged in both groups. The primary endpoint was 28-day-mortality. Results: 339 patients were enrolled. ICI was diagnosed in 48 patients (14.2%) within the first 96 h after enrollment. In the BDG-group, 48.8% (84/172) patients received antifungals during the first 96 h after enrollment and 6% (10/167) patients in the control group. Death until day 28 occurred in 58 of 172 patients (33.7%) in the BDG group and 51 of 167 patients (30.5%) in the control group (relative risk 1.10; 95% confidence interval, 0.80-1.51; p = 0.53). Median time to antifungal therapy was 1.1 [interquartile range (IQR) 1.0-2.2] days in the BDG group and 4.4 (IQR 2.0-9.1, p < 0.01) days in the control group. Conclusions: Serum BDG guided antifungal treatment did not improve 28-day mortality among sepsis patients with risk factors for but unexpected low rate of IC. This study cannot comment on the potential benefit of BDG-guidance in a more selected at-risk population.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Bloos, FrankUNSPECIFIEDorcid.org/0000-0002-0767-7941UNSPECIFIED
Held, JuergenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kluge, StefanUNSPECIFIEDorcid.org/0000-0001-8391-3988UNSPECIFIED
Simon, PhilippUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kogelmann, KlausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
de Heer, GeraldineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuhn, Sven-OlafUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jarczak, DominikUNSPECIFIEDorcid.org/0000-0003-0480-2089UNSPECIFIED
Motsch, JohannUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hempel, GuntherUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weiler, NorbertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weyland, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Druener, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gruendling, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meybohm, PatrickUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Richter, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jaschinski, UlrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Moerer, OnnenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Guenther, UlfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schaedler, DirkUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weiss, RaphaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Putensen, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Castellanos, IxchelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kurzai, OliverUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schlattmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cornely, Oliver A.UNSPECIFIEDorcid.org/0000-0001-9599-3137UNSPECIFIED
Bauer, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thomas-Rueddel, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-695859
DOI: 10.1007/s00134-022-06733-x
Journal or Publication Title: Intensive Care Med.
Volume: 48
Number: 7
Page Range: S. 865 - 876
Date: 2022
Publisher: SPRINGER
Place of Publication: NEW YORK
ISSN: 1432-1238
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
PLACEBO-CONTROLLED TRIAL; CRITICALLY-ILL PATIENTS; CARE-UNIT PATIENTS; BETA-D-GLUCAN; INVASIVE CANDIDIASIS; SEPTIC SHOCK; FUNGAL-INFECTIONS; ICU PATIENTS; HIGH-RISK; COLONIZATIONMultiple languages
Critical Care MedicineMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69585

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item